Publicaciones
-
Salud, A; Escudero, P; Feliu, J; Lopez-Gomez, L; Bolanos, M; Galan, A; Yubero, A; Vicent, JM; Losa, F; Baron, MG
XELOX (capecitabine and axaliplatin) as 1(st) line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).
Journal of Clinical Oncology 23 276-276. .
-
Hough, CL; Hudson, LD; Salud, A; Lahey, T; Curtis, JR
Death rounds: end-of-life discussions among medical residents in the intensive care unit
JOURNAL OF CRITICAL CARE 20 20-25. .
-
Porcel, JM; Vives, M; Esquerda, A; Salud, A; Perez, B; Rodriguez-Panadero, F
Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Chest 126 1757-1763. .
-
Salud, A; Saigi, E; Batiste-Alentorn, B; Losa, F; Cirera, L; Mendez, M; Campos, JM; Galan, A; Escudero, MP; Nogue, M
Randomized phase IV trial of oral tegafur and low dose leucovorin versus intravenous 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer (aCC): Final results.
Journal of Clinical Oncology 22 3547-3547. .
-
Munoz, A; Salud, A; Alonso, V; Escudero, P; Sanz, JJ; Martin, C; Rivera, F; Yubero, A; Garcia-Giron, C; Lopez-Vivanco, G
Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (La) or metastatic colorectal cancer (MCRC).
Journal of Clinical Oncology 22 3610-3610. .
-
Gravalos, C; Garcia-Giron, C; Leon, AI; Salud, A; Esteban, B; Sevilla, I; Maurel, J; Murias, A; Garcia-Rico, E; Cortes-Funes, HG
TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (aCRC): Preliminary results of a multicenter randomized phase II trial.
Journal of Clinical Oncology 22 3599-3599. .
-
Alonso, V; Salud, A; Escudero, P; Valencia, J; Mira, M; de Lobera, AR; Lambea, J; Grandez, R; Tres, A; Anton, A
Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma.
Journal of Clinical Oncology 22 3607-3607. .
-
Lopez-Gomez, L; Escudero, P; Yubero, A; Feliu, J; Salud, A; Galan, A; Bolanos, M; Vicent, JM; Losa, F; Gonzalez-Baron, M
XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).
Journal of Clinical Oncology 22 3688-3688. .
-
Feliu, J; Salud, A; Escudero, P; Lopez-Gomez, L; Pericay, C; Castanon, C; de Tejada, MRL; Rodriguez-Garcia, JM; Martinez, MP; Martin, MS; Sanchez, JJ; Baron, MG
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
BRITISH JOURNAL OF CANCER 90 1502-1507. .
-
Solans-Laque, R; Perez-Bocanegra, C; Salud-Salvia, A; Fonollosa-Pla, V; Rodrigo, MJ; Armadans, L; Simeon-Aznar, CP; Vilardell-Tarres, M
Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes.
Lupus 13 159-164. .
-
Porcel JM; Salud A; Balil A
Exoftalmos unilateral secundario a metástasis orbitaria como manifestación inicial de un cáncer de mama.
Anales De Medicina Interna 19 159-160. .
-
Morales, S; Salud, A; Balil, A; Mira, M; Garcia, E; Carceller, JA
Paclitaxel (P), gemcitabine (G) and cisplatin (c) in non-resectable non-small cell lung cancer (NSCLC).
ANNALS OF ONCOLOGY 11 527-527. .
Proyectos
- Ajuts per a la contractació de personal investigador novell (FI)
- Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
- Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
- UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
